Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02639091 · ClinicalTrials.gov registry record · Phase 1
Phase Ib Study of Anetumab Ravtansine in Combination With Pemetrexed and Cisplatin in Mesothelin-expressing Solid Tumors
A Phase 1 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT02639091 is a Phase 1 study that has completed, run by Bayer. The registered enrollment target is 36 participants.
The verdict
NCT02639091, a Phase 1 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
Determine the safety, tolerability and maximum tolerated dose of anetumab ravtansine (BAY 94-9343) in combination with pemetrexed 500 mg/m2 and cisplatin 75 mg/m2 in subjects with mesothelin-expressing predominantly epithelial mesothelioma or nonsquamous non-small-cell lung cancer.
Interventions
- DRUG Cisplatin
- DRUG Pemetrexed
- DRUG BAY 94-9343
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2016-02-03 |
| Est. Completion | 2019-10-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02639091
The ClinicalTrials.gov registry entry for NCT02639091 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Cisplatin is the first listed.
NCT02639091 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02639091 about?
NCT02639091 is a clinical study titled "Phase Ib Study of Anetumab Ravtansine in Combination With Pemetrexed and Cisplatin in Mesothelin-expressing Solid Tumors". Determine the safety, tolerability and maximum tolerated dose of anetumab ravtansine (BAY 94-9343) in combination with pemetrexed 500 mg/m2 and cisplatin 75 mg/m2 in subjects with mesothelin-expressing predominantly epithelial mesothelioma or nonsquamous non-small-cell lung cancer.
What is the current status of trial NCT02639091?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2016-02-03. Estimated completion is 2019-10-17.
What interventions are being tested in trial NCT02639091?
The interventions under investigation include: Cisplatin (DRUG), Pemetrexed (DRUG), BAY 94-9343 (DRUG).
Who is sponsoring clinical trial NCT02639091?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.